SNSW(SH:688117) Ge Long Hui A P P·2025-11-19 08:17Core Viewpoint - The approval of the raw material drug Visepegenatide by the National Medical Products Administration represents a significant milestone for the company, showcasing its comprehensive strengths in research, production, and quality management [1] Group 1: Product Approval - The company’s wholly-owned subsidiary, Chengdu Saintno Biological Pharmaceutical Co., Ltd., has received the approval notice for the listing application of Visepegenatide raw material drug [1] - The registration number for the approval is Y20230000631, and the chemical raw material drug registration standard number is YBY71372025 [1] Group 2: Product Description - Visepegenatide is a polyethylene glycol (PEG) modified exenatide that acts as a GLP-1 receptor agonist, mimicking the physiological effects of natural human GLP-1 [1] - It lowers blood sugar levels by enhancing insulin secretion in a glucose-dependent manner, making it suitable for the treatment of type 2 diabetes and obesity [1] Group 3: Implications for the Company - The approval of Visepegenatide is a testament to the company's capabilities in research and development, production, and quality management systems [1] - This achievement is expected to accumulate valuable experience for the company’s future drug research and has a positive impact on its operational development [1]